Skip to main content
MarketStoryBook
All storiesNBIX in “The Patent Cliff Sparks a Biotech Land Grab”NBIX in storiesNBIX stock

NBIX in “The Patent Cliff Sparks a Biotech Land Grab”

Neurocrine Biosciences, Inc.

Bull sideFadingExposure: not rated yet

A profitable neurology franchise and de-risked clinical pipeline give Neurocrine the commercial validation sought by acquirers needing near-term revenue.

NBIX impact map — “The Patent Cliff Sparks a Biotech Land Grab”

How this story travels from the headline to NBIX’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading NBIX impact map…

Price history, marked with story events

Oct 7, 2019 – Oct 5, 2020 · 252 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

The Patent Cliff Sparks a Biotech Land Grab

Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

BULL side — A profitable neurology franchise and de-risked clinical pipeline give Neurocrine the commercial validation sought by acquirers needing near-term revenue.

Read the full The Patent Cliff Sparks a Biotech Land Grab story

Bull side

1 story

  • NBIX in “The Patent Cliff Sparks a Biotech Land Grab”

    FadingExposure: not rated yet
    Viewing

    Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

    A profitable neurology franchise and de-risked clinical pipeline give Neurocrine the commercial validation sought by acquirers needing near-term revenue.

Bear side

1 story
  • America Imports the World's Drug Prices

    NBIX in “America Imports the World's Drug Prices”

    StableExposure: not rated yet

    US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.

    Neurocrine's earnings are concentrated in high-value branded therapies such as Ingrezza, making it exposed to reference-pricing pressure on US prices and future international launch strategy.